Remove Outcomes Remove Research Remove Transplant
article thumbnail

Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts

DAIC

THE TEXAS HEART INSTITUTE 2024 milla1cf Tue, 02/13/2024 - 17:56 February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children suffering from end-stage heart failure. The research, led by esteemed physician-scientist at The Texas Heart Institute ( THI ), Dr. James F.

article thumbnail

The impact of bleeding on outcomes following lung transplantation: a retrospective analysis using the universal definition of perioperative bleeding

Journal of Cardiothoracic Surgery

Lung transplantation (LT) represents a high-risk procedure for end-stage lung diseases. This study describes the outcomes of patients undergoing LT that require massive transfusions as defined by the universal.

article thumbnail

Standardized risk-stratified cardiac assessment and early posttransplant cardiovascular complications in kidney transplant recipients

Frontiers in Cardiovascular Medicine

Introduction Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in kidney transplant recipient (KTR). There is a dearth of standardized guidelines on optimal cardiovascular evaluation of transplant candidates. Posttransplant MACE has a negative effect on grafts and patient outcomes.

article thumbnail

Determinants of survival following heart transplantation in adults with congenital heart disease

Journal of Cardiothoracic Surgery

We examine the factors associated with heart transplant outcomes in this challenging population with complex anatomy requiring redo-sur. Adult patients surviving with congenital heart disease (ACHD) is growing.

article thumbnail

Midterm outcomes of patients with native heart recovery after Impella 5+ for cardiogenic shock

European Journal of Heart Failure

Summary of key study outcomes. Methods and results This single-centre retrospective study examined midterm (180 days) outcomes of patients with CS supported by Impella 5+ who achieved heart recovery. The objective of the study is to examine whether Impella 5.0/5.5 The average duration of Impella support was 10.5 ± 8 days.

article thumbnail

Cardiovascular Management of Patients Undergoing Hematopoietic Stem Cell Transplantation: From Pretransplantation to Survivorship: A Scientific Statement From the American Heart Association

Circulation

Hematopoietic stem cell transplantation can cure various disorders but poses cardiovascular risks, especially for elderly patients and those with cardiovascular diseases. Cardiovascular evaluations are crucial in pretransplantation assessments, but guidelines are lacking.

article thumbnail

Using stem cell-derived heart muscle cells to advance heart regenerative therapy

Science Daily - Heart Disease

Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. In a recent study, researchers tested a novel approach that involves injecting 'cardiac spheroids,' cultured from human stem cells, directly into damaged ventricles.